Maintaining Lean Body Mass When Using Weight Loss Medication.

Published Date: 27 Jan 2024

As more people take the chance of losing lean body mass, weight loss from newer drugs is unprecedented in terms of pounds lost. Dr. Eugene Lucas provides advice on how to reduce the risks for you, your patients, or both.

Read Full News

Latest News

Sep 18 2026 This Week in Cardiology

Another ESC recap, listener feedback on two trials, and a paper on GLP-1 effects on inflammation from the SELECT trial are the topics John Mandrola, MD, discusses in this week’s podcast.

Time to REACT Earlier: Is CVD Prevention Starting Too Late?

How reassuring is a low 10-year CV risk? REACT reveals how early silent atherosclerosis begins and asks whether CVD prevention should start sooner.

Never Too Late (or Too Early) for Lipid Lowering

ESC studies on statin use in patients over 70 years and identifying subclinical atherosclerosis via 3D ultrasonography of the carotid and femoral arteries and coronary CTA are discussed.

Narrative Videos to Improve Lung Cancer Screening Uptake

Short, veteran-led clips could stem fear, anxiety associated with screening

What the 2026 ESC Guidelines Mean for Primary Care

The guideline update is a revolution that will promote evidence-based, person-centered classification and management of heart failure.

Sep 11 2026 This Week in Cardiology

A second ESC recap plus two breaking stories on the failure of an investigational Lp(a) reducing drug and a new FDA approval of an AI-ECG app are covered by John Mandrola, MD

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Another ESC recap, listener feedback on two trials, and a paper on GLP-1 effects on inflammation from the SELECT trial are the topics John Mandrola, MD, discusses in this week’s podcast.

How reassuring is a low 10-year CV risk? REACT reveals how early silent atherosclerosis begins and asks whether CVD prevention should start sooner.

ESC studies on statin use in patients over 70 years and identifying subclinical atherosclerosis via 3D ultrasonography of the carotid and femoral arteries and coronary CTA are discussed.

Short, veteran-led clips could stem fear, anxiety associated with screening

The guideline update is a revolution that will promote evidence-based, person-centered classification and management of heart failure.

A second ESC recap plus two breaking stories on the failure of an investigational Lp(a) reducing drug and a new FDA approval of an AI-ECG app are covered by John Mandrola, MD

News All Time

Ergonomics of Scoping: Staying Injury Free

Drs Benjamin Levy and Patrick Young discuss how gastroenterologists can protect themselves from repetitive-motion injuries in the endoscopy suite.

When Grief Was Called Hysteria

A young woman grieving a miscarriage was labeled "hysteria." Dr Loshi Rajen reflects on diagnostic bias, the enduring power of psychiatric labels, and the importance of recognizing normal grief.

The Heart of the Matter

How a cardiac procedure exposed the tension between a mother’s autonomy and her son’s medical expertise.

The Dose Is Too High: Rethinking TKI Dosing

Standard TKI doses are often too high for long-term care. Dr Mark Kris shares his strategy for smart dose reductions that protect patient outcomes.

Optimizing Therapy in Early Stage HER2+ Breast Cancer

Cure rates are climbing, and so is the complexity of getting there. Dr Yara Abdou takes a closer look at optimizing HER2+ early-stage breast cancer therapy.

The ‘Pack-Year’ Approach to Cardiac Risk Management

The Curbsiders share practical insights on navigating complex cardiac risk factors and optimizing cholesterol.

The Looming 100-Million Cancer Workforce Crisis

Global workforce inequities are widening the cancer survival gap. Prof David Kerr highlights the stark realities and calls for an improved training approach.

Are Smart Glasses the Future of Collaborative Surgery?

Orthopedic surgeon Amgad Nakhla is using smart glasses in theater to bring remote expertise into com-plex cases and support real-time decisions.

Thyroid: A Year in Review

Drs Kaniksha Desai and Anupam Kotwal discuss thyroid: a year in review.

Fast Five Quiz: PPF Management

What do you know about the management for progressive pulmonary fibrosis? Test your knowledge with this quick quiz.

CT Radiation Risk: Is it Time to Rethink Imaging?

Two high-impact studies link routine CT scans to significant lifetime cancer risks. Dr Maurie Markman discusses why we can no longer ignore the data.

Preview: New Thyroid Nodule Guidelines

Drs Kaniksha Desai and Victor Bernet discuss the new guidelines for thyroid nodules.

Migraine and Stroke: What's the Real Risk?

Neurologist Indu Subramanian and migraine expert Andrew Charles discuss the risk for stroke in patients with migraine.

De-Escalated Treatment for Early Breast Cancer Continues to Gain Momentum

More patients of all ages skip sentinel lymph node biopsy, get less aggressive RT or none at all

Pancreatic Cancer Risk Much Higher for Certain Group, Study Suggests

Long-term follow-up of low-risk pancreatic cystic lesions may be necessary

Creeping Gradients After TAVR Linked to Poor Longer-Term Outcomes

Registry tracked incidence, prognostic impact of early hemodynamic valve deterioration

Recommended News For You

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Race, Geography Linked to Gaps in Prostate Cancer Care

Novel probes to label macrophages associated with cancer progression using a selective dye

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Time to Rethink Maintenance Pemetrexed in NSCLC?

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Circulating Tumor DNA Dynamics for Therapy Matching: A Comprehensive Clinical Review 

Quality of Life Through Personalized Survivorship Navigation After Multimodal Cancer Therapy 

Screening for Early Changes in Blood-Cell Production Capacity in Older Adults 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

AVD Chemo Regimen Shows Promise in Older Patients With HL

3.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

4.

Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions

5.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

1.

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations

2.

Contemporary Insights in Oncology in the Digital Era

3.

Strategic Concepts in Hematology for Modern Medicine

4.

Ferroptosis-Modulating Therapeutics in Precision Oncology

5.

Exploring the Potential of Bendamustine in Cancer Treatment

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Dacomitinib Case Presentation: Baseline Treatment and Current Status

2.

Blood Clotting Disorders Explained

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

Chemotherapy: What to Expect

5.

Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot